What is the mechanism of action of this treatment?

The most common treatments for endophthalmitis involve the use of antibiotics that target bacterial replication and infection. Moxifloxacin, for example, inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By preventing these processes, moxifloxacin effectively stops bacterial growth and proliferation. This mechanism is crucial for endophthalmitis patients as it helps to rapidly reduce the bacterial load in the eye, thereby minimizing damage to ocular tissues and preserving vision.

What side effects are associated with this type of intervention?

Moxifloxacin, used for treating endophthalmitis, is generally well-tolerated but can cause transient ocular discomfort in some patients. Other potential side effects include changes in visual acuity, although these are rare. When combined with corticosteroids like dexamethasone, the risk of increased intraocular pressure and cataract formation may arise. Overall, moxifloxacin's side effects are relatively mild compared to its efficacy in preventing and treating severe ocular infections.

What prior FDA approvals exist?

Moxifloxacin, a fluoroquinolone antibiotic, has been studied for its efficacy in preventing endophthalmitis, particularly through intracameral injection post-cataract surgery. This antibiotic works by inhibiting bacterial DNA gyrase and topoisomerase IV, crucial enzymes for bacterial DNA replication. While specific FDA approvals for moxifloxacin in this context are not detailed, its use aligns with the broader category of fluoroquinolones, which are known for their excellent bioavailability and effectiveness against a range of bacterial infections.

What other types of research exist?

Promising novel alternatives to Moxifloxacin for endophthalmitis treatment include: 1) Intracameral Zimoxin, which has shown efficacy in preventing endophthalmitis post-cataract surgery. 2) Newer fluoroquinolones like Delafloxacin, which offer broad-spectrum activity and enhanced efficacy. 3) Tedizolid, a newer oxazolidinone with potent activity against Gram-positive bacteria, including MRSA. These alternatives are being explored for their effectiveness and safety in clinical settings.

← Back to Search

Fluoroquinolone Antibiotic

Zimoxin for Cataract Surgery Prevention

Phase 2 & 3

Waitlist Available

Research Sponsored by Jason Ahee, M.D.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

visually significant cataracts

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up subjects will undergo eye examinations at one day, one week, and one month post-operatively

Awards & highlights

All Individual Drugs Already Approved

Approved for 10 Other Conditions

Summary

This trial tests if injecting an antibiotic called moxifloxacin into the eye after cataract surgery can prevent infections. Moxifloxacin is commonly used to prevent infections after cataract surgery. It targets patients who have had cataract surgery and aims to stop bacteria from causing infections.

Who is the study for?

This trial is for individuals with visually significant cataracts who are undergoing surgery. It's not suitable for those allergic to fluoroquinolones or cobalamin (B12).

What is being tested?

The study tests the safety and effectiveness of an eye injection called Zimoxin, which contains moxifloxacin, to prevent infection after cataract surgery compared to a placebo.

What are the potential side effects?

Possible side effects may include irritation in the eye, redness, swelling, or other signs of infection due to the moxifloxacin solution.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have cataracts that affect my vision significantly.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ subjects will undergo eye examinations at one day, one week, and one month post-operatively

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~subjects will undergo eye examinations at one day, one week, and one month post-operatively

This trial's timeline: 3 weeks for screening, Varies for treatment, and subjects will undergo eye examinations at one day, one week, and one month post-operatively for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Endophthalmitis after cataract surgery

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 10 Other Conditions

This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Treatment groupActive Control1 Intervention

Intracameral injection of moxifloxacin solution after cataract surgery

Group II: Placebo groupPlacebo Group1 Intervention

Intracameral injection of placebo after cataract surgery

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for endophthalmitis involve the use of antibiotics that target bacterial replication and infection. Moxifloxacin, for example, inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By preventing these processes, moxifloxacin effectively stops bacterial growth and proliferation. This mechanism is crucial for endophthalmitis patients as it helps to rapidly reduce the bacterial load in the eye, thereby minimizing damage to ocular tissues and preserving vision.

The Effectiveness of Intracameral Moxifloxacin Endophthalmitis Prophylaxis for Trabeculectomy.